sugammadex

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anesthesia

Conditions

Anesthesia

Trial Timeline

Sep 24, 2008 → Mar 15, 2010

NCT ID

NCT00702715

About sugammadex

sugammadex is a phase 3 stage product being developed by Merck for Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT00702715. Target conditions include Anesthesia.

What happened to similar drugs?

1 of 20 similar drugs in Anesthesia were approved

Approved (1) Terminated (0) Active (19)

✅Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofolEisaiApproved

🔄Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3

🔄Ropivacaine + BupivacaineAstraZenecaPhase 3

🔄Sugammadex + neostigmineMerckPhase 3

🔄Sugammadex + Rocuronium + Sevoflurane + PropofolMerckPhase 3

🔄Rocuronium + Sugammadex + Neostigmine + AtropineMerckPhase 3

🔄Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance doseMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05276804	Phase 3	Completed	Apr 13, 2022	Sep 3, 2024	Postoperative Urinary Retention
NCT03196167	Approved	Completed	May 13, 2017	Oct 10, 2020	Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
NCT02011490	Phase 1	Completed	Dec 11, 2013	Jun 6, 2014	Renal Insufficiency
NCT00826176	Phase 3	Completed	Jan 1, 2010	Aug 1, 2010	Anesthesia, General
NCT00702715	Phase 3	Completed	Sep 24, 2008	Mar 15, 2010	Anesthesia
NCT00535496	Phase 3	Completed	Sep 1, 2007	Feb 1, 2008	Neuromuscular Blockade
NCT00591786	Phase 2	Completed	Dec 5, 2005	Oct 19, 2006	Anesthesia, General
NCT00552929	Phase 2	Completed	Oct 4, 2005	Sep 15, 2006	Anesthesia, General
NCT00482599	Phase 3	Completed	Jun 1, 2005	Apr 13, 2006	Anesthesia, General

Competing Products

20 competing products in Anesthesia

See all competitors

Product	Company	Stage	Hype Score
Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofol	Eisai	Approved	43
arm 1 + LUSEDRA + Propofol (arm 3)	Eisai	Phase 1	29
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	26
Remimazolam Tosilate + Propofol	Jiangsu Hengrui Medicine	Phase 3	40
Remimazolam Tosylate	Jiangsu Hengrui Medicine	Phase 1	29
HR020602 injection + fentanyl injection ； remifentanil injection	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol Injection.	Jiangsu Hengrui Medicine	Phase 2	35
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	40
Sugammadex	Merck	Phase 2	35
Sugammadex	Merck	Phase 2	35
Sugammadex + neostigmine	Merck	Phase 3	40
Sugammadex + Rocuronium + Sevoflurane + Propofol	Merck	Phase 3	40
Rocuronium + Sugammadex + Neostigmine + Atropine	Merck	Phase 3	40
Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose	Merck	Phase 3	40
Rocuronium bolus maintenance + rocuronium continuous infusion maintenance	Merck	Phase 3	40
Sugammadex + Rocuronium	Merck	Phase 3	40
Sugammadex + Neostigmine	Merck	Phase 3	40
Sugammadex + Succinylcholine + Rocuronium	Merck	Phase 3	40
Rocuronium bromide + Rocuronium bromide + Rocuronium bromide + Sevoflurane + Propofol	Merck	Phase 3	40